Michael A. Banki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael A. Banki has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Steven L. Gonias
Department of Pathology, University of California San Diego, La Jolla, CA, USA
7 shared publications Andrew S. Gilder
Department of Pathology, University of California San Diego, La Jolla CA 92093, USA
4 shared publications- Pardis Azmoon
Department of Pathology, University of California San Diego School of Medicine, La Jolla, California, USA
4 shared publications - Elisabetta Mantuano
Department of Life Sciences, Health, and Health Professions, Link Campus University, 00165 Rome, Italy
3 shared publications - Coralie Brifault
Department of Pathology University of California San Diego La Jolla California
2 shared publications Donald P. Pizzo
Department of Pathology, University of California San Diego, La Jolla, California, 92093, USA
2 shared publications
Latest Publications
- 17 January 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (4) , 590-601
Enzymatically Inactive Tissue-Type Plasminogen Activator Reverses Disease Progression in the Dextran Sulfate Sodium Mouse Model of Inflammatory Bowel Disease
- 17 January 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (4) , 590-601
Enzymatically Inactive Tissue-Type Plasminogen Activator Reverses Disease Progression in the Dextran Sulfate Sodium Mouse Model of Inflammatory Bowel Disease
- Open Access
- 15 July 2018
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 131 (14)
PAI1 blocks NMDA receptor-mediated effects of tissue-type plasminogen activator on cell signaling and physiology
The fibrinolysis proteinase tissue-type plasminogen activator (tPA, also known as PLAT) triggers cell signaling and regulates cell physiology. In PC12 cells, Schwann cells and macrophages, the N-methyl-D-aspartate receptor (NMDA-R) mediates tPA signaling. Plasminogen activator inhibitor-1 (PAI1, also known as SERPINE1) is a rapidly acting inhibitor of tPA enzyme activity. Although tPA-initiated cell signaling is not dependent on its enzyme active site, we show that tPA signaling is neutralized by PAI1. In PC12 cells, PAI1 blocked the ERK1/2 activation mediated by tPA as well as neurite outgrowth. In Schwann cells, PAI1 blocked tPA-mediated ERK1/2 activation and cell migration. In macrophages, PAI1 blocked the ability of tPA to inhibit IκBα phosphorylation and cytokine expression. The cell signaling activity of tPA–PAI1 complex was rescued when the complex was formed with PAI1R76E, which binds to LRP1 with decreased affinity, by pre-treating cells with the LRP1 antagonist receptor-associated protein and upon LRP1 gene silencing. The inhibitory role of LRP1 in tPA–PAI1 complex-initiated cell signaling was unanticipated given the reported role of LRP1 as an NMDA-R co-receptor in signaling responses elicited by free tPA or α2-macroglobulin. We conclude that PAI1 functions as an inhibitor not only of the enzyme activity of tPA but also of tPA receptor-mediated activities.
- 15 July 2018
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 131 (14)
Open AccessPAI1 blocks NMDA receptor-mediated effects of tissue-type plasminogen activator on cell signaling and physiology
The fibrinolysis proteinase tissue-type plasminogen activator (tPA, also known as PLAT) triggers cell signaling and regulates cell physiology. In PC12 cells, Schwann cells and macrophages, the N-methyl-D-aspartate receptor (NMDA-R) mediates tPA signaling. Plasminogen activator inhibitor-1 (PAI1, also known as SERPINE1) is a rapidly acting inhibitor of tPA enzyme activity. Although tPA-initiated cell signaling is not dependent on its enzyme active site, we show that tPA signaling is neutralized by PAI1. In PC12 cells, PAI1 blocked the ERK1/2 activation mediated by tPA as well as neurite outgrowth. In Schwann cells, PAI1 blocked tPA-mediated ERK1/2 activation and cell migration. In macrophages, PAI1 blocked the ability of tPA to inhibit IκBα phosphorylation and cytokine expression. The cell signaling activity of tPA–PAI1 complex was rescued when the complex was formed with PAI1R76E, which binds to LRP1 with decreased affinity, by pre-treating cells with the LRP1 antagonist receptor-associated protein and upon LRP1 gene silencing. The inhibitory role of LRP1 in tPA–PAI1 complex-initiated cell signaling was unanticipated given the reported role of LRP1 as an NMDA-R co-receptor in signaling responses elicited by free tPA or α2-macroglobulin. We conclude that PAI1 functions as an inhibitor not only of the enzyme activity of tPA but also of tPA receptor-mediated activities.
- Open Access
- 14 February 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-16
The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres
PLAUR encodes the urokinase receptor (uPAR), which promotes cell survival, migration, and resistance to targeted cancer therapeutics in glioblastoma cells in culture and in mouse model systems. Herein, we show that patient survival correlates inversely with PLAUR mRNA expression in gliomas of all grades, in glioblastomas, and in the subset of glioblastomas that demonstrate the mesenchymal gene expression signature. PLAUR clusters with genes that define the more aggressive mesenchymal subtype in transcriptome profiles of glioblastoma tissue and glioblastoma cells in neurospheres, which are enriched for multipotent cells with stem cell-like qualities. When PLAUR was over-expressed or silenced in glioblastoma cells, neurosphere growth and expression of mesenchymal subtype biomarkers correlated with uPAR abundance. uPAR also promoted glioblastoma cell survival in neurospheres. Constitutively-active EGF Receptor (EGFRvIII) promoted neurosphere growth; however, unlike uPAR, EGFRvIII did not induce the mesenchymal gene expression signature. Immunohistochemical analysis of human glioblastomas showed that uPAR is typically expressed by a small sub-population of the cancer cells; it is thus reasonable to conclude that this subpopulation of cells is responsible for the effects of PLAUR on patient survival. We propose that uPAR-expressing glioblastoma cells demonstrate a mesenchymal gene signature, an increased capacity for cell survival, and stem cell-like properties.
- 14 February 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-16
Open AccessThe Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres
PLAUR encodes the urokinase receptor (uPAR), which promotes cell survival, migration, and resistance to targeted cancer therapeutics in glioblastoma cells in culture and in mouse model systems. Herein, we show that patient survival correlates inversely with PLAUR mRNA expression in gliomas of all grades, in glioblastomas, and in the subset of glioblastomas that demonstrate the mesenchymal gene expression signature. PLAUR clusters with genes that define the more aggressive mesenchymal subtype in transcriptome profiles of glioblastoma tissue and glioblastoma cells in neurospheres, which are enriched for multipotent cells with stem cell-like qualities. When PLAUR was over-expressed or silenced in glioblastoma cells, neurosphere growth and expression of mesenchymal subtype biomarkers correlated with uPAR abundance. uPAR also promoted glioblastoma cell survival in neurospheres. Constitutively-active EGF Receptor (EGFRvIII) promoted neurosphere growth; however, unlike uPAR, EGFRvIII did not induce the mesenchymal gene expression signature. Immunohistochemical analysis of human glioblastomas showed that uPAR is typically expressed by a small sub-population of the cancer cells; it is thus reasonable to conclude that this subpopulation of cells is responsible for the effects of PLAUR on patient survival. We propose that uPAR-expressing glioblastoma cells demonstrate a mesenchymal gene signature, an increased capacity for cell survival, and stem cell-like properties.
- Open Access
- 1 November 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (45) , 18699-18712
Shedding of membrane-associated LDL receptor-related protein-1 from microglia amplifies and sustains neuroinflammation
- 1 November 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (45) , 18699-18712
Open AccessShedding of membrane-associated LDL receptor-related protein-1 from microglia amplifies and sustains neuroinflammation
- Open Access
- 14 September 2017
- Published by American Society of Hematology in Blood
- Vol. 130 (11) , 1364-1374
Tissue-type plasminogen activator regulates macrophage activation and innate immunity
Key Points: Tissue-type plasminogen activator inhibits the activity of the innate immune system in macrophages in vitro and in vivo in mice. Suppression of macrophage proinflammatory responses by tPA requires the NMDA receptor.
- 14 September 2017
- Published by American Society of Hematology in Blood
- Vol. 130 (11) , 1364-1374
Open AccessTissue-type plasminogen activator regulates macrophage activation and innate immunity
Key Points: Tissue-type plasminogen activator inhibits the activity of the innate immune system in macrophages in vitro and in vivo in mice. Suppression of macrophage proinflammatory responses by tPA requires the NMDA receptor.
- Open Access
- 10 January 2017
- Published by Wiley in The FASEB Journal
- Vol. 31 (4) , 1744-1755
Ionotropic glutamate receptors activate cell signaling in response to glutamate in Schwann cells
In the peripheral nervous system, Schwann cells (SCs) demonstrate surveillance activity, detecting injury and undergoing trans ‐differentiation to support repair. SC receptors that detect peripheral nervous system injury remain incompletely understood. We used RT‐PCR to profile ionotropic glutamate receptor expression in cultured SCs. We identified subunits required for assembly of N ‐methyl‐D‐aspartic acid (NMDA) receptors (NMDA‐Rs), α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptors, and kainate receptors. Treatment of SCs with 40–100 μM glutamate or with 0.5–1.0 μM NMDA robustly activated Akt and ERK1/2. The response was transient and bimodal; glutamate concentrations that exceeded 250 μM failed to activate cell signaling. Phosphoprotein profiling identified diverse phosphorylated proteins in glutamate‐treated SCs in addition to ERK1/2 and Akt, including p70 S6‐kinase, glycogen synthase kinase‐3, ribosomal S6 kinase, c‐Jun, and cAMP response element binding protein. Activation of SC signaling by glutamate was blocked by EGTA and dizocilpine and by silencing expression of the NMDA‐R NR1 subunit. Phosphoinositide 3‐kinase/PI3K functioned as an essential upstream activator of Akt and ERK1/2 in glutamate‐treated SCs. When glutamate or NMDA was injected directly into crush‐injured rat sciatic nerves, ERK1/2 phosphorylation was observed in myelinated and nonmyelinating SCs. Glutamate promoted SC migration by a pathway that required PI3K and ERK1/2. These results identified ionotropic glutamate receptors and NMDA‐Rs, specifically, as potentially important cell signaling receptors in SCs. —Campana, W. M., Mantuano, E., Azmoon, P., Henry, K., Banki, M. A., Kim, J. H., Pizzo, D. P., Gonias, S. L. Ionotropic glutamate receptors activate cell signaling in response to glutamate in Schwann cells. FASEB J . 31, 1744–1755 (2017) www.fasebj.org
- 10 January 2017
- Published by Wiley in The FASEB Journal
- Vol. 31 (4) , 1744-1755
Open AccessIonotropic glutamate receptors activate cell signaling in response to glutamate in Schwann cells
In the peripheral nervous system, Schwann cells (SCs) demonstrate surveillance activity, detecting injury and undergoing trans ‐differentiation to support repair. SC receptors that detect peripheral nervous system injury remain incompletely understood. We used RT‐PCR to profile ionotropic glutamate receptor expression in cultured SCs. We identified subunits required for assembly of N ‐methyl‐D‐aspartic acid (NMDA) receptors (NMDA‐Rs), α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptors, and kainate receptors. Treatment of SCs with 40–100 μM glutamate or with 0.5–1.0 μM NMDA robustly activated Akt and ERK1/2. The response was transient and bimodal; glutamate concentrations that exceeded 250 μM failed to activate cell signaling. Phosphoprotein profiling identified diverse phosphorylated proteins in glutamate‐treated SCs in addition to ERK1/2 and Akt, including p70 S6‐kinase, glycogen synthase kinase‐3, ribosomal S6 kinase, c‐Jun, and cAMP response element binding protein. Activation of SC signaling by glutamate was blocked by EGTA and dizocilpine and by silencing expression of the NMDA‐R NR1 subunit. Phosphoinositide 3‐kinase/PI3K functioned as an essential upstream activator of Akt and ERK1/2 in glutamate‐treated SCs. When glutamate or NMDA was injected directly into crush‐injured rat sciatic nerves, ERK1/2 phosphorylation was observed in myelinated and nonmyelinating SCs. Glutamate promoted SC migration by a pathway that required PI3K and ERK1/2. These results identified ionotropic glutamate receptors and NMDA‐Rs, specifically, as potentially important cell signaling receptors in SCs. —Campana, W. M., Mantuano, E., Azmoon, P., Henry, K., Banki, M. A., Kim, J. H., Pizzo, D. P., Gonias, S. L. Ionotropic glutamate receptors activate cell signaling in response to glutamate in Schwann cells. FASEB J . 31, 1744–1755 (2017) www.fasebj.org
- Open Access
- 29 September 2015
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 18 (5) , 667-678
Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature
In glioblastoma (GBM), the gene for epidermal growth factor receptor (EGFR) is frequently amplified. EGFR mutations also are common, including a truncation mutation that yields a constitutively active variant called EGFR variant (v)III. EGFRvIII-positive GBM progresses rapidly; however, the reason for this is not clear because the activity of EGFRvIII is attenuated compared with EGF-ligated wild-type EGFR. We hypothesized that EGFRvIII-expressing GBM cells selectively express other oncogenic receptors that support tumor progression. Mining of The Cancer Genome Atlas prompted us to test whether GBM cells in culture, which express EGFRvIII, selectively express vascular endothelial growth factor receptor (VEGFR)2. We also studied human GBM propagated as xenografts. We then applied multiple approaches to test the effects of VEGFR2 on GBM cell growth, apoptosis, and cellular senescence. In human GBM, EGFR overexpression and EGFRvIII positivity were associated with increased VEGFR2 expression. In GBM cells in culture, EGFRvIII-initiated cell signaling increased expression of VEGFR2, which prevented cellular senescence and promoted cell cycle progression. The VEGFR-selective tyrosine kinase inhibitor cediranib decreased tumor DNA synthesis, increased staining for senescence-associated β-galactosidase, reduced retinoblastoma phosphorylation, and increased p27Kip1, all markers of cellular senescence. Similar results were obtained when VEGFR2 was silenced. VEGFR2 expression by GBM cells supports cell cycle progression and prevents cellular senescence. Coexpression of VEGFR2 by GBM cells in which EGFR signaling is activated may contribute to the aggressive nature of these cells.
- 29 September 2015
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 18 (5) , 667-678
Open AccessSelective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature
In glioblastoma (GBM), the gene for epidermal growth factor receptor (EGFR) is frequently amplified. EGFR mutations also are common, including a truncation mutation that yields a constitutively active variant called EGFR variant (v)III. EGFRvIII-positive GBM progresses rapidly; however, the reason for this is not clear because the activity of EGFRvIII is attenuated compared with EGF-ligated wild-type EGFR. We hypothesized that EGFRvIII-expressing GBM cells selectively express other oncogenic receptors that support tumor progression. Mining of The Cancer Genome Atlas prompted us to test whether GBM cells in culture, which express EGFRvIII, selectively express vascular endothelial growth factor receptor (VEGFR)2. We also studied human GBM propagated as xenografts. We then applied multiple approaches to test the effects of VEGFR2 on GBM cell growth, apoptosis, and cellular senescence. In human GBM, EGFR overexpression and EGFRvIII positivity were associated with increased VEGFR2 expression. In GBM cells in culture, EGFRvIII-initiated cell signaling increased expression of VEGFR2, which prevented cellular senescence and promoted cell cycle progression. The VEGFR-selective tyrosine kinase inhibitor cediranib decreased tumor DNA synthesis, increased staining for senescence-associated β-galactosidase, reduced retinoblastoma phosphorylation, and increased p27Kip1, all markers of cellular senescence. Similar results were obtained when VEGFR2 was silenced. VEGFR2 expression by GBM cells supports cell cycle progression and prevents cellular senescence. Coexpression of VEGFR2 by GBM cells in which EGFR signaling is activated may contribute to the aggressive nature of these cells.